MPH Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Medicure Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$1.17 |
52 Week High | CA$1.80 |
52 Week Low | CA$0.92 |
Beta | 0.97 |
11 Month Change | 8.33% |
3 Month Change | 10.38% |
1 Year Change | -17.61% |
33 Year Change | -4.10% |
5 Year Change | -75.11% |
Change since IPO | -89.17% |
Recent News & Updates
Recent updates
Estimating The Fair Value Of Medicure Inc. (CVE:MPH)
May 14Investors Don't See Light At End Of Medicure Inc.'s (CVE:MPH) Tunnel
Mar 08We Ran A Stock Scan For Earnings Growth And Medicure (CVE:MPH) Passed With Ease
Aug 28Medicure's (CVE:MPH) Earnings Are Weaker Than They Seem
Nov 30Here's Why Shareholders Should Examine Medicure Inc.'s (CVE:MPH) CEO Compensation Package More Closely
Jun 15Shareholder Returns
MPH | CA Biotechs | CA Market | |
---|---|---|---|
7D | 14.7% | -0.3% | 1.8% |
1Y | -17.6% | -44.1% | 10.1% |
Return vs Industry: MPH exceeded the Canadian Biotechs industry which returned -41.1% over the past year.
Return vs Market: MPH underperformed the Canadian Market which returned 8.4% over the past year.
Price Volatility
MPH volatility | |
---|---|
MPH Average Weekly Movement | 12.4% |
Biotechs Industry Average Movement | 12.3% |
Market Average Movement | 8.1% |
10% most volatile stocks in CA Market | 16.8% |
10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: MPH has not had significant price volatility in the past 3 months.
Volatility Over Time: MPH's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | n/a | Albert Friesen | www.medicure.com |
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia.
Medicure Inc. Fundamentals Summary
MPH fundamental statistics | |
---|---|
Market cap | CA$12.21m |
Earnings (TTM) | -CA$1.16m |
Revenue (TTM) | CA$21.76m |
0.6x
P/S Ratio-10.5x
P/E RatioIs MPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MPH income statement (TTM) | |
---|---|
Revenue | CA$21.76m |
Cost of Revenue | CA$7.67m |
Gross Profit | CA$14.09m |
Other Expenses | CA$15.25m |
Earnings | -CA$1.16m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.11 |
Gross Margin | 64.75% |
Net Profit Margin | -5.34% |
Debt/Equity Ratio | 0% |
How did MPH perform over the long term?
See historical performance and comparison